Home > Focus Areas > Obesity Connect > Post
  • Saved

5h
Integrating oral GLP-1 pathways into obesity care: clinical decisions beyond initiation

As obesity care continues to evolve, clinical focus is shifting from initiating therapy to managing obesity as a long-term, relapsing condition. Recent advances in oral glucagon-like peptide-1 (GLP-1) receptor agonist development reinforce this shift, prompting clinicians to consider not only whether to use pharmacologic therapy, but how it can be integrated into sustained, multidimensional care plans over time.

GLP-1 receptor activation influences appetite regulation, satiety signaling, and metabolic pathways central to obesity pathophysiology. Oral formulations demonstrate that these mechanisms can be engaged through daily administration, expanding how clinicians think about treatment design and long-term engagement. This evolution brings renewed attention to clinical integration—how pharmacologic therapy aligns with behavioral strategies, lifestyle interventions, and ongoing monitoring rather than functioning as a stand-alone solution.

Patient selection and adherence remain central considerations in long-term obesity management. Functional factors such as daily dosing routines, gastrointestinal tolerability, and treatment fatigue—as well as emotional factors including expectations, motivation, and prior weight-loss experiences—may influence sustained use and outcomes. These considerations highlight the importance of shared decision-making and regular reassessment as patient needs and priorities evolve.

Rather than viewing therapy choice as a single decision point, many clinicians are approaching obesity care as a dynamic process that requires adjustment over time. Evidence-based strategies increasingly emphasize structured follow-up, realistic goal-setting, behavioral support, and coordinated, multidisciplinary care. Within this framework, oral GLP-1 approaches may offer flexibility across different phases of treatment, including escalation, stabilization, or maintenance.

What factors most influence how you select patients for long-term pharmacologic obesity therapy?As oral GLP-1 options enter clinical practice, what adherence challenges or integration considerations will most shape how you incorporate them into comprehensive obesity care?

Profile Image
  • 5h
    In obesity care, the decision to start long-term medication like GLP-1 therapy usually comes down to a mix of clinical need and real-life readiness. It’s not just about BMI or a single cut-off—it’s more about whether someone’s weight is continuing to cause health problems, whether they’ve struggled to maintain weight loss with lifestyle changes alone, and whether there’s a clear sense that biology is driving regain rather than effort or motivation. Just as important is whether the patient actually feels ready for something that may be ongoing, rather than temporary, and whether their expectations match what these medications can realistically do over time.
    With oral GLP-1 options, the day-to-day realities matter even more than the pharmacology. Taking something every day sounds simple, but in practice it depends on routines, side effects, and how the person feels about being “on treatment” long term. Some patients find an oral option easier to live with, while others struggle with consistency or lose momentum once early results level off. The biggest challenge is often not starting the medication, but keeping it going in a way that still feels worthwhile as life gets busy, motivation shifts, and obesity is managed as something ongoing rather than something that has a clear endpoint.
  • 6h
    When considering long-term pharmacologic therapy for obesity, I look beyond BMI alone and focus on the broader clinical picture. Factors such as obesity-related comorbidities, previous weight-loss attempts, quality-of-life impact, and the patient's readiness to engage in long-term treatment all play an important role in the decision-making process.

    As oral GLP-1 options become more widely available, I think adherence will be one of the most important considerations. Some patients may prefer an oral option over injections, but success will still depend on managing expectations, tolerability, daily treatment routines, and ongoing support. Ultimately, the greatest benefit is likely to come when these therapies are integrated into a comprehensive care plan that includes lifestyle interventions, regular follow-up, and realistic long-term goals.
  • 19h
    I’d start with the bigger question: what is making weight harder to manage for this patient, and what kind of support would actually work for them? Medical history, daily habits, access, side effects, and past frustrations all shape the decision. Oral GLP 1s may help, but they still need follow up, patience, and a plan the patient can keep up with beyond the first few months.
  • Yesterday
    The factors that most influence how I select patients for long-term pharmacologic obesity therapy extend beyond BMI thresholds to include demonstrated readiness for behavioral engagement specifically, patients who have already attempted structured lifestyle modifications (e.g., consistent food logging, activity tracking, or prior nutrition counseling) and who articulate realistic expectations about weight loss magnitude (e.g., 5-15% rather than "transform to a normal BMI"). As oral GLP-1 options enter practice, the adherence challenges that will most shape my integration strategy are the daily dosing burden itself (which requires patients to adhere to strict fasting windows typically 30-60 minutes before the first food or drink of the day a hurdle that injectable weekly formulations avoid) and the need to manage gastrointestinal tolerability (nausea, vomiting, diarrhea) without reflexively discontinuing therapy. The integration consideration that will most influence my approach is how to pair daily oral GLP-1 use with existing behavioral frameworks: I anticipate needing to build explicit protocols around missed dose management, dose escalation schedules that accommodate work and travel routines, and regular reassessment of treatment fatigue at 3, 6, and 12 months, while also identifying which patients might paradoxically do better with a daily ritual (those who thrive on routine) versus those who will struggle with daily adherence and would benefit more from weekly injectable options.
  • Yesterday
    When choosing who gets long-term obesity medication, I look at their BMI, weight-related health problems, past success with diet and exercise, and whether they’re ready to commit to taking it regularly. Oral GLP-1s are exciting because people often prefer pills over shots, but their strict timing rules and early stomach upset can make them hard to stick with. We also still need to learn how well they work long-term compared to injectable versions, and how to fit them into people’s busy daily lives. The key will be pairing these new pills with ongoing lifestyle coaching and regular check-ins, since medication alone can’t change the habits that drive weight gain.
  • Yesterday
    BMI ≥30 or ≥27 with comorbidity, failure to maintain ≥5% weight loss with lifestyle alone, patient understanding of chronic therapy, and no contraindications (eating disorder, MEN2, medullary thyroid cancer history).

    Daily nausea and slow titration needs; fasting requirements disrupting routines; treatment fatigue; and mandatory concurrent behavioral program with 12-week weight loss checkpoint to justify continuation.
  • Yesterday
    I choose patients for long-term weight medication based on their BMI, any weight-related health conditions, what they’ve tried before, and if they’re prepared to stick with treatment long-term. I also look at how safe the drug is, what it costs, and what the patient feels comfortable with, so it’s something they can actually keep up with. Now that oral GLP‑1s are available, the biggest issues for staying on track are remembering the strict dosing rules, dealing with stomach side effects, and building a consistent daily routine. They work well for people who prefer not to take shots, but I always pair them with diet and activity changes and check how they mix with other medicines. They give us more options, but it still comes down to regular check-ins and making sure the whole plan fits their life.
  • Yesterday
    I select patients for long-term medication mainly based on their BMI, whether they have weight-related health issues, and how well they’ve stuck to lifestyle changes so far, while also checking for any health risks or cost barriers. When it comes to the new oral GLP-1 options, I know many will prefer them over injections, but I also have to be clear about the strict rules for taking them correctly. I expect some people will still struggle with side effects or the routine timing of doses, which I’ll need to address early on to keep them consistent. Ultimately, I see these medicines as part of a full care plan rather than a standalone fix, so I’ll combine them with regular support and realistic goals to help patients stay on track long-term.
  • Yesterday
    Obesity treatment is becoming more of a long-term, ongoing process, where oral GLP-1 medications are just one part of the overall plan. In real practice, the decision to use them often comes down to whether a patient is ready for consistent, long-term treatment, can manage daily dosing, and has realistic expectations about results and side effects. The biggest challenge usually isn’t starting the medication but sticking with it over time, especially when motivation changes or side effects come up. Because of that, care tends to focus on combining medication with lifestyle support and regular follow-up, adjusting the plan as needed to fit the patient’s life rather than treating it as a one-time decision.
  • Yesterday
    I’d choose therapy by looking at the full picture: what health problems are tied to the weight, what the patient has tried before, and what they can realistically keep doing. Oral GLP 1s may be appealing, but they still require consistency, patience, and support. The plan has to feel manageable, not like another burden added to the patient’s day.
  • Yesterday
    I choose patients for long-term anti-obesity medication primarily based on clinical criteria: BMI ≥30 or ≥27 with conditions like diabetes, hypertension, or sleep apnea; prior unsuccessful lifestyle efforts; no safety contraindications; and clear willingness to commit to ongoing care. I also factor in cardiometabolic risk profile, weight-related disability, and stability of mental health.
    As oral GLP-1 agonists become standard practice, adherence hurdles include required fasting/separation from other drugs, persistent nausea or GI upset, higher daily pill burden, cost barriers, and misunderstanding that therapy is chronic, not temporary. When integrating them, I prioritize patient preference, simplify dosing where possible, monitor for drug interactions, and combine treatment with diet, activity, and regular follow-up to maximize persistence and outcomes.
  • Yesterday
    When choosing patients for long term obesity medication, I focus on health risk, safety, readiness, access, and ability to stay engaged with follow up care. With oral GLP 1 options, the biggest challenges will be daily use, side effects, expectations, cost, and treatment fatigue. These medications work best as part of a full care plan with nutrition, activity, behavior support, monitoring, and shared decision making.
  • Yesterday
    I primarily consider factors like BMI, the presence of weight-related health conditions, how much progress they’ve made with lifestyle changes, and their willingness to commit to ongoing treatment, while also ruling out any safety concerns or reasons not to use medication. For oral GLP‑1s, the main barriers to consistent use include the need to take them on an empty stomach, common digestive side effects, and the routine of remembering a daily dose. I also take into account how they interact with other medications, their effectiveness compared to injectable forms, and whether they are affordable and accessible over time. They work well as a preferred option for patients who want to avoid injections, but I always integrate them with diet, physical activity, and regular follow‑ups to support long‑term success.
  • Yesterday
    The factors that most influence how I select patients for long-term pharmacologic obesity therapy are: a history of previous weight regain after behavioral or lifestyle interventions, presence of obesity-related comorbidities (e.g., prediabetes, hypertension, NAFLD, or OSA) that would benefit from sustained weight loss even if BMI is not extremely elevated, and patient commitment to indefinite treatment with regular follow-up—since obesity is a chronic relapsing condition, I explicitly avoid initiating therapy in anyone who views medication as a short-term "jumpstart" without a plan for maintenance. As oral GLP-1 options enter clinical practice, the adherence challenges and integration considerations that will most shape my approach are: managing gastrointestinal tolerability (e.g., nausea, delayed gastric emptying) with slow dose titration and clear instructions on timing relative to meals, addressing treatment fatigue related to daily oral administration (compared to weekly injectables), and coordinating care across primary care, nutrition, and behavioral health to ensure that pharmacotherapy enhances rather than replaces lifestyle counseling. The biggest integration consideration for me is establishing a structured maintenance protocol after active weight loss—specifically, identifying the minimum effective maintenance dose for each patient, planning for scheduled "adherence check-ins" at 3, 6, and 12 months to reassess benefit versus side effects, and having upfront conversations about what to do if weight plateaus or financial access changes, including contingency plans for transition between oral and injectable formulations based on patient preference and tolerability.
  • 2d
    I select patients based on BMI, weight-related health issues, whether lifestyle changes alone have worked, their motivation, and any safety risks. I also factor in cost, access, and if they’re ready for long-term care.
    With oral GLP‑1s, the main adherence challenges are strict dosing rules—empty stomach, waiting to eat, and daily routine, plus stomach side effects. I fit them in for those who hate needles, but I also watch how well they follow instructions and make sure they still get diet and activity support.
  • 2d
    Selection for long-term obesity pharmacotherapy is primarily guided by body mass index, presence of weight-related comorbidities, and evidence that lifestyle modifications alone have not achieved sufficient results. Equally important are the patient’s overall health status, absence of contraindications, and willingness to engage in ongoing care and monitoring. For oral GLP-1 agonists, key adherence challenges include strict dosing requirements, persistent gastrointestinal side effects, and cost barriers that can limit consistent use. Successful integration depends on clear patient education, gradual dose adjustment, and combining medication with sustained lifestyle and behavioral support.
  • 2d
    When selecting patients for long-term obesity medication, I would look beyond BMI and consider their overall health risks, past weight-loss experiences, treatment goals, motivation, medication tolerability, cost, and ability to stay consistent with follow-up care. As oral GLP-1 options become available, adherence will be an important factor because taking a daily pill may be more convenient for some patients, but side effects, missed doses, treatment fatigue, and unrealistic expectations can still affect success. I would view oral GLP-1 therapy as one part of a broader, long-term obesity care plan that includes lifestyle changes, behavioral support, regular monitoring, and shared decision-making.
  • 2d
    Patient selection for long-term pharmacologic obesity therapy starts with reframing the conversation entirely. I find that patients who understand obesity as a chronic relapsing condition rather than a personal failure are significantly more likely to sustain engagement over time. Beyond BMI and comorbidities, I weigh behavioral readiness, prior treatment history, and whether the patient has realistic expectations about the trajectory of weight loss, including the likelihood of needing long-term maintenance therapy.

    With oral GLP-1 options, the adherence challenge I anticipate most is the dosing ritual itself. Strict fasting requirements, timing relative to other medications, and daily consistency create friction that weekly injectables simply don't have. I see oral formulations fitting best as a maintenance option for patients who have achieved meaningful weight loss on injectables, or as an entry point for needle-averse patients who might otherwise decline therapy altogether. Either way, pharmacotherapy without structured behavioral support and regular reassessment will underperform regardless of the delivery route.
  • 3d
    I select patients for long‑term pharmacotherapy based on BMI category, weight‑related comorbidities, and a clear history that lifestyle changes alone have not delivered meaningful results. Motivation, realistic expectations, and willingness to engage in regular follow‑up are just as critical, as they directly shape consistency and success. With oral GLP‑1 options, I anticipate managing adherence hurdles like daily dosing and GI tolerance, so I start low, titrate gradually, and pair medication with behavioral support to build sustainable, whole‑person care.
  • 3d
    Patient selection depends on BMI level, weight‑related comorbidities, and limited success with lifestyle changes alone. Motivation, prior weight management history, and willingness for regular follow‑up also play key roles. Oral GLP‑1 agents bring new considerations: daily dosing and gastrointestinal tolerance are common adherence hurdles. I integrate them by starting low, titrating slowly, and combining therapy with diet, activity, and behavioral support to build sustainable long‑term care.
  • 3d
    Patient selection for long‑term pharmacotherapy in obesity is guided by a composite of clinical, metabolic, and psychosocial factors: the degree and duration of excess adiposity, the presence of weight‑related comorbidities such as type 2 diabetes, hypertension, or obstructive sleep apnea, and documented insufficient response to structured lifestyle modification. Equally important are the patient’s intrinsic motivation, realistic expectations regarding outcomes, prior history of weight management efforts, and willingness to engage in regular follow‑up—all of which determine the likelihood of sustained adherence.

    With the introduction of oral GLP‑1 receptor agonists, new considerations come into play: daily dosing requirements, gastrointestinal tolerability, and the potential for treatment fatigue over time can pose significant adherence barriers. To integrate these agents effectively, I initiate therapy at the lowest effective dose, titrate gradually to minimize side effects, and frame treatment as part of a broader, lifelong health strategy rather than a short‑term intervention. By combining pharmacotherapy with behavioral support, dietary counseling, and ongoing monitoring of both efficacy and safety, we can leverage the flexibility of oral GLP‑1 options to support durable weight management and metabolic improvement.
  • 3d
    I select patients for long‑term obesity pharmacotherapy based on their degree of excess weight, presence of related health conditions, and whether lifestyle changes alone have been insufficient, while also weighing their motivation, prior experiences, and willingness to commit to ongoing care. As oral GLP‑1 agents become available, key considerations include managing daily dosing routines, gastrointestinal tolerability, and the risk of treatment fatigue, which can impact long‑term adherence. I integrate these medications by starting at conservative doses, monitoring for side effects, and combining them with behavioral support and regular reassessment, ensuring they fit seamlessly into a sustainable, comprehensive plan focused on lasting health benefits.
  • 3d
    Patient selection for long-term pharmacologic obesity therapy is mainly guided by degree of obesity, obesity-related comorbidities (such as type 2 diabetes, hypertension, or sleep apnea), prior response to lifestyle interventions, and overall readiness for sustained treatment. I also consider psychosocial factors, including motivation, eating behavior patterns, and ability to engage in follow-up, since obesity management requires long-term adherence rather than short-term use.

    With oral GLP-1 therapies, the main integration challenges are adherence to daily dosing, gastrointestinal side effects, and maintaining long-term motivation once early weight loss stabilizes. In practice, success depends on combining pharmacologic therapy with structured lifestyle support, regular monitoring, and ongoing patient education to sustain engagement and prevent weight regain.
  • 3d
    Patient selection for long-term obesity pharmacotherapy is influenced by BMI, obesity-related comorbidities, prior weight-loss attempts, motivation, readiness for behavior change, and the ability to engage in ongoing follow-up. I also consider whether the patient views treatment as part of a long-term management strategy rather than a short-term intervention.

    With oral GLP-1 therapies, adherence considerations include daily dosing requirements, gastrointestinal tolerability, treatment expectations, cost, and long-term persistence. Successful integration will likely depend on combining medication with lifestyle counseling, realistic goal-setting, regular monitoring, and ongoing behavioral support to maintain engagement and durable weight-loss outcomes.
  • 3d
    When choosing patients for long-term obesity medication, I’d look beyond weight alone and consider their overall health risks, past weight-loss experiences, safety concerns, access to treatment, and how ready they are for ongoing care. With oral GLP-1 options, the biggest challenges will likely be remembering daily doses, managing stomach-related side effects, cost, and staying motivated over time. For these treatments to work well, they need to be part of a bigger care plan that includes lifestyle support, realistic goals, regular check-ins, and honest conversations about what the patient can sustain.
  • 3d
    I select patients for long-term pharmacotherapy based on their weight-related health risks, prior efforts with lifestyle changes, and their readiness and motivation to sustain treatment. Tolerability, especially gastrointestinal side effects, and the practical fit of daily dosing also play key roles in keeping patients consistent over time. As oral GLP‑1 options become available, I see adherence challenges centered on consistent daily intake, managing side effects, and avoiding treatment fatigue. They work best when integrated as part of a broader plan that includes behavioral support, regular check‑ins, and clear goals rather than being used in isolation.
  • 3d
    I focus on patients who have clear health risks tied to their weight and show willingness to make ongoing lifestyle changes alongside medication. For oral GLP‑1s, the main challenges will be sticking to a daily routine, managing digestive side effects, and keeping motivated when progress slows. I plan to integrate them as a flexible tool within full, personalized care—combining them with diet, activity, and regular follow‑up rather than relying on them alone.
  • 4d
    Patient selection is primarily influenced by the severity of obesity, associated comorbidities, motivation for sustained treatment, and insurance coverage. The primary obstacles to effective oral GLP-1 administration are cost, compliance with daily dosing, and gastrointestinal tolerability. I combine pharmacotherapy with lifestyle changes, consistent follow-up, and continuous behavioral support to enhance long-term results.
  • 4d
    When choosing patients for long-term weight-management medication, I focus first on clinical need—such as BMI level and associated conditions like diabetes or hypertension—alongside the patient’s personal readiness, commitment to ongoing care, and understanding that therapy works best alongside lifestyle changes. For oral GLP‑1 agents specifically, practical factors like daily dosing routine, potential digestive side effects, and the ability to stay consistent over time will shape how I prescribe them. I see these medications as one component of a full care plan, not a standalone fix, so I work to combine them with regular check-ins, behavioral support, and clear, flexible goals to help patients stay engaged and get the most benefit long-term.
  • 5d
    I select patients based on BMI, weight‑related comorbidities, and a history of engagement with lifestyle changes to ensure they are ready for long‑term care.
    For oral GLP‑1s, the main challenges are daily adherence, GI tolerability, and avoiding treatment fatigue over time.
    They fit best as part of a full plan—combined with behavioral support and regular follow‑up—rather than as a standalone solution.
  • 6d
    I mostly look at their BMI, weight related health issues like diabetes or joint pain, how well they’ve stuck to diet and exercise before, and whether they’re ready to commit long term. With oral GLP-1s, the biggest hurdles are remembering strict empty stomach rules, dealing with nausea or stomach upset, and making sure they fit around other daily medicines. I also have to think about cost, consistent daily use compared to shots, and checking regularly that they’re working safely alongside the rest of their care plan.
  • 6d
    I base my selection mostly on a patient’s BMI, existing weight-related health conditions, their past efforts with lifestyle changes, and their personal readiness to commit long-term. With oral GLP-1s now becoming available, the biggest hurdles will be consistent daily use, managing stomach side effects, and making sure patients can stick with the routine compared to injections. I’ll also need to fit them smoothly into overall care,monitoring how they work alongside other medicines, keeping up with regular check-ins, and keeping expectations realistic about results.
  • 6d
    I look at their BMI, related health conditions, and how much progress they’ve made with diet and exercise first, plus whether they’re prepared to stick with treatment long-term. Cost, safety, and what they feel comfortable with also play a big part in my choice. Oral GLP-1s are great because they avoid injections, but remembering to take them correctly on an empty stomach every day can be tricky. I also watch for stomach side effects and make sure they understand this is ongoing support, not just a short-term solution.
  • 3w
    Selecting patients for long-term pharmacologic obesity therapy is heavily influenced by framing obesity as a chronic, relapsing condition that requires an evaluation of baseline metabolic profiles alongside key behavioral, functional, and emotional factors. When incorporating oral GLP-1 receptor agonists into long-term care, adherence challenges are most sharply shaped by a patient's daily dosing routines, gastrointestinal tolerability, and the development of long-term treatment fatigue. To mitigate these hurdles, oral approaches must be intentionally integrated into multi-dimensional, coordinated care plans that combine pharmacotherapy with structured lifestyle interventions, realistic goal-setting, and regular shared decision-making. This flexible framework allows clinicians to dynamically adjust treatment across different escalation, stabilization, and maintenance phases as the patient's individual priorities evolve over time.
  • 3w
    First question is usually how much weight do they need to lose and what comobid conditions do they have. If I can get a GLP1 covered based on co morbid condition then that's what I will use. Otherwise will taylor to the patient preference and cost. Usually cost is the primary driver for the patient
  • 1mo
    I am most concerned as to whether a pt has any comorbitities that will interfere with their administration of these drugs. There may be some long term side effects from these drugs that may not have been detected.
  • 1mo
    They are good for patients who need 10-12% TBW . Ongoing trials with aleniglipron from Structure therapeutics which could bring this number to 15% if approved by FDA. They are also good if patients who lost weight on injectables ( Wegovy, Zepbound) want to transition to oral maintenance therapy but here comes Pfizer with their 10 billion $ buyout of Metsera for a monthly GLP1RA which if approved could be a blockbuster
  • 1mo
    These medications assist patients in long term weight loss. I consider if the patient is able to inject the medication or prefer oral.
  • 1mo
    Percentage of weight loss desired and needle phobia are key factors . Magnitude of GI adverse side effects alo plays a role to ensure successful titration
  • 1mo
    GLP-1 therapy is good for obese PT’s. I am

    concerned about the long term side effects. There have been some reports on the news media about weakness in the lower extremities. More research needs to be done on the

    long term side effects.
  • 2mo
    the need, so bmi in overweight/obesity/morbidly obese range and the tolerability and affordability of the medication

    again side effects and effective weight loss are all clinical factors that play a role in using a medication like this as well as insurance coverage and patient compliance, also knowing the respective patient is doing more than just relying on this medicine for their overall health and healthy weight maintenance
  • 2mo
    With the new orforglipron approval by the FDA more oral GLP1RA options are for the US market , both covered and non covered by insurance . Hopefully adhetence to these medications will increase if the price is right.
  • 2mo
    Oral Wegovy has no insurance coverage at this time. I prescribe it for patients who don't mind paying the cash price for it. It is by far the cheapest option for cash paying patients at this time who want a GLP1 medication for weight loss. I also prescribe it for needle phobic patients who desire weight loss.
  • 2mo
    cost
  • 3mo
    Great drugs for treatment of obesity and diabetes but patients needs to compliant w diet and exercise. Needs to change lifestyle if not will regain all the weight loss
  • 3mo
    GLP-1 have been proven to be effective in most patient with obesity, diabetes and cardiovascular risks. Unfortunately, the cost is prohibitive and many patients relapse-- regain weight after weaning off the medication. The most benefit is achieved if patient is maintained on medication for long-term. As oral GLP1 become available, affordability would be a real concern similar to SGLT2i and other newer medications.
  • 3mo
    GLP-1's have been a boon not only for obesity, but for a whole host of serious diseases.
  • 3mo
    GLP-1 agents have favorable effects on multiple organ systems and are proving to have benefits beyond glucose lowering. That being said, the cost of this class of medication limits access to large parts of the patient population. The need to remain on these agents places a significant financial burden on the healthcare system.
  • 3mo
    GLP-1 are amazing and safe sources for treating DM and overweight patients.
  • 3mo
    Obesity is a disease process and need to be treated aggressively. GLP-1's are an excellent resource
  • 3mo
    Obesity needs to be considered a chronic illness and treated like any other chronic illness such as hypertension or diabetes. GLP1 an agents provide excellent options for treatment but treatment needs to be approached as a chronic therapy. Oral agents provide an excellent option for maintenance treatment after initial weight loss with injectables.
  • 3mo
    What factors most influence how you select patients for long-term pharmacologic obesity therapy?

    I discuss with the patient that starting a GLP-1 medication is a long term commitment, not only to taking the med but covering the cost of the medication. This is often a burden to the patient. If the patient balks at this commitment, I know they are not a good candidate for the meds.

    As oral GLP-1 options enter clinical practice, what adherence challenges or integration considerations will most shape how you incorporate them into comprehensive obesity care?

    I have found getting patient compliance with oral GLP1 meds is actually harder than with injections due to increased GI side effects.
  • 3mo
    GLP-1 Agonist are great boon for Obesity management and for the first time we have the class of medicine which help pts improve the satiety rather than just the appetite supression so it helps in conditioning to the food intake that you di not have to eat as much to feel satiated ! So by and large management of obesity now pivots around this class and have so many choices and the most prescribed product is Semaglutide brand name and the compounded ones with proven efficacy and poisitice CV , Diabetes and Renal outcomes ! So they are an obvious choice in the long term management of obesity and it is a chronic disease and to manage it need a long term therapeutic intervention along with regular diet and exercise program the importance of which can not be over emphasized . Injectable Semaglutide has been widely used and have most experience with and have observed the proven efficacy and safety and now oral Wegovy is available I still prefer injectable to oral as it definetly improves the compliance however oral pill has its place in needle phobic pts and have seen it in the form of Rybelsus in diabetic pts as well So with the oral form available it will for sure enhance its use and dose titration will be some what easier in pts having difficulty in injectable am sure if compliant with the oral form will see the same results so all in all it is a very optimistic landscape for the management of obesity !!
  • 3mo
    I commonly use GLP-1 inhibitors in obesity treatment. With the introduction of oral GLP-1 medicine, it will need to be seen how effective they are compared to injectables and how well it is tolerated. I will be waiting until more data is provided before I offer the oral formulation over the injectable
  • 3mo
    Patients needs to be motivated to be compliant with medication/diet and exercise. Needs to achieve lifetime goals once they stop the medication they gain weight back. Definitely helps to loose weight/ improve lipid profiles as well as fatty liver and if they are diabetic improve HGA1C as well as cardio renal protection
  • 3mo
    I consider GLP-1 inhibitors to be a tool to add to a patient who struggles with obesity to reduces future complications and risk. I do anticipate that in the future we will have data showing increased longevity due to this management. Quality of life is most important and these medications help people who suffer with this condition. Obstacles to care have been problematic but that is so common with newer medication classes. It happened 40 years ago with statins.
    I consider GLP-! therapy to be long term barring any medical complications and most patients agree.
  • 3mo
    I have many patients who both qualify and ask for these agents. The biggest barrier for them currently is cost. Although the direct to consumer cost is slightly lower than last year, and now the daily oral option is available, which is slightly less expensive than the injectables, it is still difficult to initiate these treatments and keep the patients on them for maintenance therapy due to the impact on their pocketbooks. I have many patients who previously underwent bariatric surgery and regained much of their weight, now requesting these drugs. I have felt the oral agents are likely not good options for these patients, but for others who do not have a history of surgery and fear needles, they certainly are a good candidates for the oral product. I like to follow up with these patients at a minimum every 8-12 weeks as they are initiating therapy and encourage them along the way to integrate strength training and high protein diets to maintain muscle mass during their weight loss journey. I do fear if they do not stay on at least some maintenance of these medications they will regain their weight. These agents are a part of my daily discussions with patients who would benefit from weight loss - particularly my diabetes, patients with cardiovascular disease, patients with sleep apnea and MASH.
  • 3mo
    I have alot of patients who qualify for these agents. Since jan 1 rarely does any insurance cover them anymore. About 85% of my patiuents are stopping due to cost alone. Those who can afford will obtain through Lilly direct pharmacy or Trump . I use BMI as a criteria and look at risk factors for patients(Diabetes, CAD, sleep apnea, MASH etc,) and look for any contraindications for GLP-1 use. Lots of my patients qualify.
  • 3mo
    I am a big fan of this class of drugs. I look at patients BMI, abdominal fat content(w/h ratio) and contraindications if any. Otherwise they are good to go. I still prefer SQ once a week over oral once a day Not to wait to take on fasting stomach , freq etc. CV and renal benefits are amazing
  • 3mo
    Akram Sadaka

    I was probably among the first group of providers who utilized GLP1 in the management of obesity for many years starting with Victoza, to Saxenda, to Ozempic, and now Wegovy. while GLP-1 is proven to be effective, safe, and well tolerated, I found subset of patients who find the injectable form is less convenient and somewhat less practical for them particularly those who are on the go all the time and the travelers. Upon request from those individuals, I prescribed Rybelsus off-label to them and worked for them. Now that Wgovy pills became available, I find it attractive and very useful in that subset of obese patients.
  • 3mo
    The most important factor in selecting patients is their personal motivation. Did they initiate the process? Are they motivated to do the work necessary to achieve their goals? Can they afford the therapy? In addition to cost, another barrier is that a significant number of patients find that the therapy fails to provide adequate appetite suppression and/or sustained weight loss over time.
  • 3mo
    I was probably among the first group of providers who utilized GLP1 in the management of obesity for many years starting with Victoza, to Saxenda, to Ozempic, and now Wegovy. while GLP-1 is proven to be effective, safe, and well tolerated, I found subset of patients who find the injectable form is less convenient and somewhat less practical for them particularly those who are on the go all the time and the travelers. Upon request from those individuals, I prescribed Rybelsus off-label to them and worked for them. Now that Wgovy pills became available, I find it attractive and very useful in that subset of obese patients.
  • 3mo
    I was probably among the first group of providers who utilized GLP1 in the management of obesity for many years starting with Victoza, to Saxenda, to Ozempic, and now Wegovy. while GLP-1 is proven to be effective, safe, and well tolerated, I found subset of patients who find the injectable form is less convenient and somewhat less practical for them particularly those who are on the go all the time and the travelers. Upon request from those individuals, I prescribed Rybelsus off-label to them and worked for them. Now that Wgovy pills became available, I find it attractive and very useful in that subset of obese patients.
  • 3mo
    I discuss patients level of obesity, risk factors, health problems and then discuss options for GLP-1 weight loss treatment=injection certainly for higher bmi's and oral options for lower bmi's. Adherence challenges are typically cost and formulary. Patients certainly do well with these meds and lose substantial weight, but cost can be a problem frequently. Hopefully, more insurance companies will cover. IF patient has diabetes, moderate to severe sleep apnea or Fatty liver with liver fibrosis, certainly much easier to get covered.
  • 3mo
    The need to take GLP-1 agents indefinitely makes oral GLP-1 agents more attractive to needle-averse patients. Cost and insurance coverage will continue to be major barriers to wide use
  • 3mo
    It’s a shared decision with the patient keeping in mind their other comorbidities like ckd , osa , heart conditions . Most important factor ultimately is the insurance coverage and cost . Oral glp are more affordable but less effective. Ultimately patient preference and side effects have a play as well . Direct drug company deals like lily direct and financial plans can be helpful .
  • 3mo
    Obesity is medical problem that has significant impact a plethora of areas. If a patient can afford effective therapy, I think it is a disservice not to provide effective therapy for a problem that can have devastating health impacts. I try to target known indications to match medication to patient (someone has psoriasis I am more likely to use tirzepatide, someone has CKD I will more likely use semaglutide). I think oral GLP-1 specifically the wegovy with the SNAC coating which can minimize side effects are a very promising option to help get over needle phobia. I do think the injections are probably more effective with less long term concerns regarding gut inflammation.
  • 3mo
    I will mainly reserve oral GLP1s for maintenance treatment in patients who have achieved the desired weight loss. Daily medications are a challenge as far as compliance is concerned. I have started some patients on oral Wegovy who are needle phobic and would not accept an injectable option.
  • 3mo
    Multiple factors affect patient selection for GLP-1, including patients who fit the obesity criteria, patient preference, patient expectation, and most importantly insurance coverage. The cost is the main challenge we see. The oral GLP-1 options are more cost effective (currently cash pay cost is $150 per month) and is much more affordable to many patients than the injectable GLP-1. The fact that patients are unable to eat or drink anything for 30 minutes after taking the oral GLP-1 will likely become a challenge. I do believe the integration of oral GLP-1 will help reach more patients.
  • 3mo
    Comorbidity profiles and health benefits significantly influence medication selection. I will use oral GLP-1s based on shared decision making and also use them for long term weight loss maintenance. I utilized BMI thresholds inadequate response to lifestyle interventions, and individual patient factors including comorbidities, contraindications, preferences, and access to therapy (their insurance plans); although many are open to self pay options. The oral GLP-1 may enhance compliance and also convince those needle phobic patients to accept this treatment option.
  • 3mo
    As long as patients are tolerating it well and losing weight or not gaining, I continue their GLP-1, whatever dose they are on.
  • 3mo
    Selection is influenced by patient motivation, cost and GI tolerability. Oral agents are more appealing to patients but not less expensive and often less well tolerated. A patient support program is most effective at fostering weight loss results. Drug company financial assistance programs are very helpful.
  • 3mo
    Attempts at weight loss and expectations. Orals are also a challenge in how they need to be taken. If meds are needed for weight loss, they are likely needed to keep the weight off as well.
  • 3mo
    A patient will need to have reasonable expectations regarding the limitations of this therapy. Insurance coverage or lack thereof is a major driver of prescriptions for oral agents. The need to take oral agents on an empty stomach can be a deal-breaker
  • 3mo
    Prior authorization and insurance coverage. Patients tolerance and getting good coverage for patients in their insurance which is easier but sometimes takes longer
  • 3mo
    Explaining the risks of obesity and benefit of losing weight, explain different options to lose weight, we have to adjust to what medications are covered but the process is getting easier.
  • 3mo
    The initial evaluation of patients must include a detailed discussion about the possibility of needing to take GLP1a medications life long. It’s not a quick fix and just like other chronic illnesses Obesity is one as well and needs long term management. Challenges include insurance coverage and patient tolerability. A large proportion of patients who meet criteria for GLP1a drugs do have underlying conditions such as heart failure , CKD , OSA for which these drugs are a great addition as well.
  • 3mo
    After talking with my patient, if they show interest and meet criteria for weight loss with GLP 1 we discuss options. Insurance dictates which GLP 1 patient starts with (if even has insurance coverage for this) if not we review the cost going through Novo Care and Lily direct
  • 3mo
    Yes GLP 1 medications oral and subq injections are an integral part of the treatment for obesity in my clinic. the problem is the insurance coverage. i do use a compounding pharmacy or lilly direct, novocare, costco has also helped with wegovy coverage at affordable price.
    the adherence challenges are the constipation and the potential for decreased blood flow to the gut. we have seen an increase in mesentaric artery stenosis requiring surgery. this is yet another concern with these meds. we way the risk/benefit when patient starts these medications. overall they are an excellent class of meds and once patient is using them and effective a game changer for obesity.
  • 4mo
    If my patient is motivated, has no contraindications, and BMI over 30 I will offer GLP-1, but insurance is the gatekeeper. My office has a Prior Auth team (1 person) and this is helpful, but the P.A. process is long and frustrating for the patient and the prescriber. I expect the same hoops to jump through for oral GLPs.
  • 4mo
    Patient preference, insurance coverage and side effects profile is all considerations on which one to select. There has been a oral GLP-1 in the past known as rybelsus and it was a nightmare for side effects and after trying patients on it I gave up since no one seemed to tolerate this medication. So my input on oral GLP-1 is very hesitant due to potential side effects of nausea/vomiting. However this med has potential but I'm not the first in line to prescribe it. I'd prefer injectable GLP-1s since it's been tried and true for so long now and patients generally tolerate this very well and the dosing is titrated on a monthly basis.
  • 4mo
    A lot of the decision is associated with secondary benefit. If patient have cardiovascular or renal risk, then something like Wegovy is the better option. So as far as the Oral option it's about patient choice. If you prefer oral, then that's the way to go. Often the weekly injection is more convenient. It doesn't make any difference to me. I try to be flexible in terms of form and dosing to keep the weight loss slow and steady and to keep patients at their goal once they are there.
  • 4mo
    Patient preference for delivery. Current oral option has unique requirements but very manageable. Insurance dictates choice however in products. Long term treatment appears necessary for most.

Show More Comments